Tempest Therapeutics, Inc. (TPST) intrinsic value & 10-year financials
Tempest Therapeutics, Inc. (TPST) has a Graham intrinsic value of $552.34 per share. At $0.62 on Oct 17, 2026, the stock trades 100% below that value.
- Graham intrinsic value
- $552.34
- Share price (Oct 17, 2026)
- $0.62
- Price vs Graham value
- 100% below
- Market cap
- $2.6M
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- -54.8%
- ROIC (10-yr avg)
- 488.4%
- Free cash flow (FY2025)
- -$26.8M
TPST 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$26.3M | -$6.33 | -$26.8M | — | -573.7% |
| FY2024 | — | -$41.8M | -$1.50 | -$33.5M | — | -792.9% |
| FY2023 | — | -$29.5M | -$1.91 | -$27.5M | — | -393.2% |
| FY2022 | — | -$35.7M | -$3.09 | -$31.6M | — | -772.8% |
| FY2021 | — | -$28.3M | -$2.49 | -$26.1M | — | 3001.8% |
| FY2020 | — | -$36.4M | -$1.71 | -$30.5M | — | 1657.3% |
| FY2019 | — | -$44.6M | — | -$41.6M | — | 3049.5% |
| FY2018 | — | -$27.2M | — | -$23.7M | — | -114.7% |
| FY2017 | $295.0K | -$51.0M | — | -$45.7M | -17154.6% | -102.9% |
| FY2016 | $653.0K | -$82.3M | — | -$64.3M | -12406.1% | -74.9% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Tempest Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Tempest Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -24.1% ROIC.
Tempest Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Tempest Therapeutics, Inc. is modeled at -54.8% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $552.34 per share.